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Individual PR Values Post-Ticagrelor 360 mg LD and
180 mg LD
Individual values of platelet reactivity at 0, 0.5, 1, 2, and 4 h post-ticagrelor
360 mg LD (red dots) and 180 mg LD (gray dots), as assessed with the Ver-
ifyNow assay in PRU. Lines represent medians, and error bars represent inter-
quartile range. The high platelet reactivity threshold (208 PRU) is shown with the
dotted line. LD ¼ loading dose; PR ¼ platelet reactivity; PRU ¼ platelet reaction
units.To the Editor: Early and strong platelet inhibition is highly desir-
able in patients with ST-segment elevation myocardial infarction
(STEMI) undergoing primary percutaneous coronary intervention
(PCI). Ticagrelor, which has direct action on the P2Y12 receptor
and no need for previous metabolic activation, provides faster
platelet inhibition than clopidogrel (1,2). In patients with stable
coronary artery disease or acute coronary syndrome, ticagrelor has
been administered as a 180-mg loading dose (LD), leading to
marked inhibition of platelet reactivity within 1 h, with almost all
patients below the predeﬁned cutoff points of high platelet reac-
tivity (HPR) (1,3). However, in the acute phase of STEMI, we
recently reported a delayed onset of antiplatelet action, with more
than one-half of patients exhibiting HPR at 1 h post-treatment
with a 180-mg LD of ticagrelor (4). Because the mean maximum
concentration and area under the curve for ticagrelor and its
main metabolite AR-C124910XX increased approximately dose-
proportionately in healthy volunteers treated with 50 to 600 mg
of ticagrelor once daily (5), we hypothesized that doubling the
standard 180-mg LD of ticagrelor might lead to a faster onset of its
antiplatelet action.
We performed a prospective, 4-center, nonrandomized, con-
trolled study in 2 sequential groups of P2Y12 inhibitor-naive
consecutive patients with STEMI undergoing primary PCI.
After a 325-mg LD of aspirin, patients were treated with 360 mg
or 180 mg ofticagrelor. We excluded patients with a history of
stroke/transient ischemic attack, oral anticoagulation, hemody-
namic instability, platelet count <100,000/ml, hematocrit <30%,
creatinine clearance <30 ml/min, severe hepatic dysfunction,
increased risk of bradycardia, severe chronic obstructive pulmonary
disease, or periprocedural administration of IIb/IIIa inhibitors.
Platelet reactivity (PR) was assessed at hour 0 (before adminis-
tration of ticagrelor immediately before PCI) and at hours 0.5, 1,
2, and 4 thereafter. Platelet function testing (in platelet reaction
units [PRU]) was performed with the VerifyNow (Accumetrics
Inc., San Diego, California) P2Y12 function assay. The propensity
score of exposure to a double LD was estimated with a logistic
regression model ﬁt with sex, diabetes mellitus, smoking, use of
bivalirudin, creatinine clearance <60 ml/min, and age 75 years as
categorical variables and hematocrit, platelet count, pain-to-
balloon time, body mass index, and PR at baseline as continuous
variables (C-statistic: 0.725; 95% conﬁdence interval [CI]: 0.612 to
0.838). Differences in PR between groups were analyzed via
a mixed-effect model with treatment as a ﬁxed effect, patient as
a random intercept, and PR at baseline and propensity score as
covariates. Least squares estimates of the mean difference with
95% CI are presented for the treatment effect. HPR rates
(thresholds 230 PRU and 208 PRU) were calculated. All tests
were 2-tailed, and statistical signiﬁcance was considered for
p values <0.05. Statistical analyses were performed using SPSS forWindows (version 16.0; SPSS Inc., Chicago, Illinois). The study
protocol was approved by the ethics committee of each partici-
pating hospital. All patients provided written informed consent
before participation in the study.
PR was assessed in 45 and 38 patients treated with a double
and standard LD, respectively. In total, 86.7% were men, with
a median (quartile 1 to quartile 3) age of 54 (48.0 to 65.0) years and
pain-to-balloon time of 3.5 (2.0 to 5.3) h. No signiﬁcant differ-
ences in demographic and clinical characteristics were observed
between groups (Online Table 1). Individual PR values are shown
in Figure 1. PR least squares mean difference (95% CI) between
groups at 0.5, 1, 2, and 4 h post-loading was 11.9 (34.1 to
10.2), 6.3 (29.1 to 41.7), 11.4 (37.6 to 60.3), and 19.5 (9.7 to
48.8) with p ¼ 0.3, p ¼ 0.7, p ¼ 0.6, and p ¼ 0.2, respectively
(Online Table 2). HPR rates did not differ signiﬁcantly between
groups at any time post-LD (Online Tables 3 and 4). During in-
hospital observation, minor bleeding events (bruising) were
observed in 3 patients treated with a double LD patients and one
patient treated with a standard LD.
Because the magnitude of platelet inhibition has been associated
with plasma ticagrelor concentrations (5), we speculated that
doubling of the LD might achieve a high drug concentration earlier
than the standard dose, which would provide faster onset of anti-
platelet activity. This hypothesis was not conﬁrmed in our study.
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941Intravenous antiplatelet agents such as IIb/IIIa inhibitors or can-
grelor may offer a bridge for this initial delay of antiplatelet action
of ticagrelor administered as either a standard or double LD.
Alternatively, earlier (i.e., pre-hospital) administration of ticagrelor
may lead to better platelet inhibition during primary PCI. The
clinical utility of this strategy is being tested by the ongoing
ATLANTIC study (NCT01347580).
Our study was not randomized; however, demographic and
clinical characteristics were balanced between patients treated with
a double and a standard LD. Furthermore, a propensity score was
used to adjust for potential biases. The study was purely pharma-
codynamic, not allowing any conclusions on clinical outcome. We
used only 1 method for platelet function testing; however, Ver-
ifyNow is the most validated method and correlates well with light
transmittance aggregometry. The lack of pharmacokinetic data
does not allow elucidation of the exact mechanisms responsible for
the double LD delayed onset of action of ticagrelor. In this small
study, a double LD was well tolerated, which is consistent with
a previous report (5).
In patients with STEMI undergoing primary PCI, doubling the
LD of ticagrelor is not accompanied by a faster than standard dose
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of Acute Myocardial Infarction in
Skeletal Muscle Disease Patients
Follow the Guidelines
In a recent letter to the editor of the Journal (1), Rittoo describes
what he calls a “fundamental error” in the guidance documents on
the diagnosis of acute myocardial infarction (AMI), namely, in the
universal deﬁnition of AMI (2) and the expert consensus (3), with
potential implications for the detection of AMI during increased
skeletal muscle repair or disease events. In particular, Rittoo infers
from 3 references (4–6), with overlapping authorship, that diseased
skeletal muscle may re-express cardiac troponin T (cTnT), but not
cTnI, which may then lead to elevated cTnT in serum. The author
further states that the guidance documents wrongly deﬁne eleva-
tions of the marker in the circulation as “virtually diagnostic of
myocardial necrosis.”
In our view, Rittoo’s statements were incorrect and misleading
for several reasons. First, the suspected cardiac (un)speciﬁcity of
cTnT could not be derived from the cited references (4–6). For
example, the ﬁrst study (4) compared different cTnT antibody
generations and concluded that “circulating cTnT or cTnI in either
end-stage renal disease (ESRD) or Duchenne muscular dystrophy
(DMD) patients originates from the heart” (and not from skeletal
muscle), which was in contrast to Rittoo’s interpretation of these
data. In the second cited reference (5), the bands in the Western
blot analyses of DMD had a smaller molecular weight (molecular
mass 33 to 39 kDa) compared with that from heart muscle or
puriﬁed protein, suggesting that different cTnT isoforms were
observed; importantly, it was found that the Roche antibody M7
was not reactive to these smaller cTnT isoforms (7). The different
antibody reactivity therefore illustrates the utmost importance of
including more than 1 antibody for both cTnT and cTnI isoforms
when drawing general conclusions on their cardiac speciﬁcity and
